scispace - formally typeset
G

Goonaseelan Pillai

Researcher at University of Cape Town

Publications -  40
Citations -  1340

Goonaseelan Pillai is an academic researcher from University of Cape Town. The author has contributed to research in topics: Population & Tuberculosis. The author has an hindex of 15, co-authored 36 publications receiving 1193 citations. Previous affiliations of Goonaseelan Pillai include Hoffmann-La Roche & Novartis.

Papers
More filters
Journal ArticleDOI

Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.

TL;DR: Recent studies indicate that the pattern of markers during bisphosphonate treatment may be predictive of antifracture efficacy; however, only limited data are available for the development of pharmacokinetic/pharmacodynamic models that are able to predict the response of these markers to different treatment regimens with bisph phosphonates.
Journal ArticleDOI

Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions

TL;DR: Though further refinement is needed to accurately predict the behavior of these drugs in human subjects, the results enable the integration of lesion-specific pharmacokinetic-pharmacodynamic (PK-PD) indices in clinical trial simulations and in in vitro PK-PD studies with M. tuberculosis.
Journal ArticleDOI

Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption

TL;DR: A strong correlation between clearance and volume of distribution suggested substantial variability in bioavailability, which could have clinical implications, given the dependence of treatment effectiveness on exposure.
Journal ArticleDOI

Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.

TL;DR: Simulations suggested that current treatment guidelines may be suboptimal in fast eliminators with low body weight, which may lead to underexposure in rapid isoniazid eliminators.
Journal ArticleDOI

Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

TL;DR: A historical summary of the development of non-linear mixed effects modeling up to the more recent extensions of this statistical methodology and places strong emphasis on the pivotal role played by Lewis B. Sheiner (1940–2004).